Medical Management of Toxic Megacolon

[1]  A. Griffiths,et al.  Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. , 2014, Gastroenterology.

[2]  P. Rutgeerts,et al.  Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. , 2014, Gastroenterology.

[3]  G. Radford-Smith,et al.  Outcomes of salvage therapy for steroid‐refractory acute severe ulcerative colitis: ciclosporin vs. infliximab , 2013, Alimentary pharmacology & therapeutics.

[4]  Laurent Beaugerie,et al.  Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. , 2013, Journal of Crohn's & colitis.

[5]  John T. Chang,et al.  Strategies for the care of adults hospitalized for active ulcerative colitis. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[6]  J. Gisbert,et al.  Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial , 2012, The Lancet.

[7]  S. Vermeire,et al.  Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Current management , 2012 .

[8]  R. Erichsen,et al.  Thirty-day mortality after elective and emergency total colectomy in Danish patients with inflammatory bowel disease: a population-based nationwide cohort study , 2012, BMJ Open.

[9]  J. Gisbert,et al.  Infliximab salvage therapy after failure of ciclosporin in corticosteroid‐refractory ulcerative colitis: a multicentre study , 2012, Alimentary pharmacology & therapeutics.

[10]  A. Kornbluth,et al.  Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee , 2010, The American Journal of Gastroenterology.

[11]  A. Gasbarrini,et al.  Infliximab in severe ulcerative colitis: short‐term results of different infusion regimens and long‐term follow‐up , 2007, Alimentary pharmacology & therapeutics.

[12]  S. Xiao,et al.  Meta‐analysis: the utility and safety of heparin in the treatment of active ulcerative colitis , 2007, Alimentary pharmacology & therapeutics.

[13]  S. Danese,et al.  Inflammation and Coagulation in Inflammatory Bowel Disease: The Clot Thickens , 2007, The American Journal of Gastroenterology.

[14]  Å. Danielsson,et al.  Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. , 2005, Gastroenterology.

[15]  P. Beck,et al.  A new look at toxic megacolon: an update and review of incidence, etiology, pathogenesis, and management , 2003, American Journal of Gastroenterology.

[16]  P. Rutgeerts,et al.  Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. , 2003, Gastroenterology.

[17]  A. Kornbluth,et al.  Ulcerative colitis practice guidelines in adults , 1997 .

[18]  D. Jewell,et al.  Predicting outcome in severe ulcerative colitis. , 1996, Gut.

[19]  D. Jewell,et al.  Intensive intravenous regimen for severe attacks of ulcerative colitis. , 1974, Lancet.

[20]  R. Prescott,et al.  An Experience of Ulcerative Colitis , 1970 .

[21]  W. Card,et al.  An experience of ulcerative colitis. I. Toxic dilation in 55 cases. , 1969, Gastroenterology.